Epidemiological EMESIS-Registry

Epidemiologic Registry for the Description of Antiemetic Strategies Under Real-life Conditions.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00911222

Acronym

EMESIS

Enrollment

1035

Registered

2009-06-01

Start date

2008-10-31

Completion date

2009-08-31

Last updated

2014-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiemetic Therapy

Keywords

antiemetic therapy, emesis, vomiting, nausea, moderately and highly emetogenic chemotherapy, cisplatin, carboplatin, oxaliplatin, anthracycline, cyclophosphamid

Brief summary

The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate complete and major control of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.

Interventions

OTHERnon-interventional

non-interventional

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid. * start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given \>= 24 months ago. * Compliance with registry procedures * Age \>= 18 years * WHO Performance Status of 0 or 1 (Karnofsky-Index \>= 70%) * Life expectancy of at least 12 weeks * Signed and dated informed consent before the start of the registry

Exclusion criteria

* Mentally incapable or incompliant patients * Last chemotherapy \<= 24 months (if pretreated) * Known hypersensitivity to antiemetic medication * unability of the patient to be treated with oral medication * pregnancy or lactation period

Design outcomes

Primary

Measure	Time frame
Efficacy of anti-emetic therapies dependent on the rate complete and major control of nausea and emesis in moderately and highly emetogenic chemotherapy regimens.	4 chemotherapy applications per patient

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026